Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen

Por Blumenstein, Brent, Saad, Fred, Hotte, Sebastien, Chi, Kim N, Eigl, Bernhard, Gleave, Martin, Jacobs, Cindy
Publicado em 2013

Using a Powered Bone Marrow Biopsy System Results in Shorter Procedures, Causes Less Residual Pain to Adult Patients, and Yields Larger Specimens

Por Berenson, James R, Yellin, Ori, Blumenstein, Brent, Bojanower, Deanna, Croopnick, Jonathan, Aboulafia, David, Upadhyaya, Gargi, Spadaccini, Cathy
Publicado em 2011

Improved Endpoints for Cancer Immunotherapy Trials

Por Hoos, Axel, Eggermont, Alexander M. M., Janetzki, Sylvia, Hodi, F. Stephen, Ibrahim, Ramy, Anderson, Aparna, Humphrey, Rachel, Blumenstein, Brent, Old, Lloyd, Wolchok, Jedd
Publicado em 2010

Enhancing Patient-Provider Communication With the Electronic Self-Report Assessment for Cancer: A Randomized Trial

Por Berry, Donna L., Blumenstein, Brent A., Halpenny, Barbara, Wolpin, Seth, Fann, Jesse R., Austin-Seymour, Mary, Bush, Nigel, Karras, Bryant T., Lober, William B., McCorkle, Ruth
Publicado em 2011

Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer

Por Church, Timothy Robert, Wandell, Michael, Lofton-Day, Catherine, Mongin, Steven J, Burger, Matthias, Payne, Shannon R, Castaños-Vélez, Esmeralda, Blumenstein, Brent A, Rösch, Thomas, Osborn, Neal, Snover, Dale, Day, Robert W, Ransohoff, David F
Publicado em 2014

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Por Kantoff, Philip W., Schuetz, Thomas J., Blumenstein, Brent A., Glode, L. Michael, Bilhartz, David L., Wyand, Michael, Manson, Kelledy, Panicali, Dennis L., Laus, Reiner, Schlom, Jeffrey, Dahut, William L., Arlen, Philip M., Gulley, James L., Godfrey, Wayne R.
Publicado em 2010